Navigation Links
GenVec Reports Third Quarter 2009 Financial Results
Date:11/5/2009

ds. The decrease in both periods is primarily due to lower personnel costs, professional fees, reduced patient, site, lab, data management, monitoring and materials costs related to our TNFerade(TM) program, reduced materials costs related to our funded programs, and reduced general lab materials and supplies.

GenVec ended the third quarter of 2009 with $14.2 million in cash and investments.

"Based on existing contracts and collaborations, we anticipate revenues for 2009 will be between $14.0 million and $16.0 million. We project our cash burn to be between $12.0 million and $14.0 million for the 12 months ending September 30, 2010 although our spending will be heavily influenced by the availability of capital," commented Douglas J. Swirsky, GenVec's Senior Vice President and Chief Financial Officer. "Our primary focus remains on TNFerade and the PACT trial and we look forward to sharing additional data from this pivotal trial next year."

Third Quarter and Recent Highlights

  • GenVec has enrolled 277 patients in the pivotal PACT trial as of October 31, 2009.
  • GenVec's lead product candidate, TNFerade, was granted orphan drug designation by the FDA. Orphan drug designation provides potential financial and regulatory incentives including study design assistance, waiver of FDA user fees, tax credits, and up to seven years of market exclusivity upon marketing approval.
  • GenVec signed a contract with the SAIC for the development of influenza and HIV vaccines in support of the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Disease (NIAID), part of the National Institutes of Health (NIH). This four-year contract has a total value of over $22 million if all options are exercised. Over the next year, GenVec will receive approximately $2.6 million under the base year of the contract.
  • GenVec was awarded an approximately $2.5 million Small Business Innovation and
    '/>"/>

SOURCE GenVec, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants
2. GenVec Expands Contract Supporting Malaria Vaccine Program
3. GenVec Reports Second Quarter 2009 Financial Results
4. GenVec Receives an Approximately $2.5 Million Grant to Support Novel Cell Line Development
5. GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants
6. GenVec Announces Third Quarter 2009 Results Conference Call
7. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
8. QMed, Inc. Reports July Medicare SNP Enrollments
9. Phlo Affiliate Reports Expanded Coverage to Oregon Border
10. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
11. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... ST. LOUIS , June 2, 2015 /PRNewswire/ ... leading Life Science and Technology company, announced today ... XCell Science to launch genetically engineered human ... to advance the research of neurological diseases. These ... portfolio, provide unique and versatile tools for the ...
(Date:6/2/2015)... 02, 2015 Through rare discovery of ... Yancy Corporation is enabling World Scientists to actually ... biological sample, displaying the full nature (position, shape, size, ... , Jeff Porter, Co-Founder of the Yancy Corporation, says, ... – rare. They come once in a lifetime, if ...
(Date:6/1/2015)... YORK , June 1, 2015  Turing ... researcher  Eliseo Oreste Salinas , MD, MSc,  has ... development. Dr. Salinas, who holds a ... pharmacology, brings a record of significant accomplishments in ... psychiatry.  Dr. Salinas has played a ...
(Date:6/1/2015)... YORK , June 1, 2015 ... by the fermentation of sugar or cellulose. Bio-alcohols are ... can be used as a replacement for gasoline in ... grow at a CAGR of 9 percent over the ... The global bio-alcohols market can be segmented into five: ...
Breaking Biology Technology:Sigma-Aldrich to Launch XCell Science Genetically Engineered iPSC-Derived Neural Disease Cells 2Sigma-Aldrich to Launch XCell Science Genetically Engineered iPSC-Derived Neural Disease Cells 3Scientists Eying Rare Discovery Of New Physics & Light Microscope Technology 2Turing Pharmaceuticals Names Eliseo Salinas, MD and MSc, President of Research and Development 2Turing Pharmaceuticals Names Eliseo Salinas, MD and MSc, President of Research and Development 3Global Bio-alcohols Market 2015-2019 2
... ... ... var shortURL = ... need to grab the first one. for (var r in data.results) { first_result = data.results[r]; break; } for (var ...
... 2010 Kendle (Nasdaq: KNDL ), a ... business awards for the third quarter of 2010 of ... quarter moderated significantly to $10.4 million or 1.3 percent ... in a net book-to-bill of 1.5. New business authorizations ...
... DST Health Solutions, LLC, today launched new versions ... Advance, PowerMHC, PowerMHS and PowerSTEPP. The platforms now support ... & Medicaid Services (CMS). This change—from Version 4010/4010A to ... effective Jan. 1, 2012, as designated by CMS. ...
Cached Biology Technology:Oncothyreon Reports Third Quarter 2010 Financial Results 2Oncothyreon Reports Third Quarter 2010 Financial Results 3Oncothyreon Reports Third Quarter 2010 Financial Results 4Oncothyreon Reports Third Quarter 2010 Financial Results 5Oncothyreon Reports Third Quarter 2010 Financial Results 6Oncothyreon Reports Third Quarter 2010 Financial Results 7Oncothyreon Reports Third Quarter 2010 Financial Results 8Oncothyreon Reports Third Quarter 2010 Financial Results 9Oncothyreon Reports Third Quarter 2010 Financial Results 10Oncothyreon Reports Third Quarter 2010 Financial Results 11Kendle Announces Third Quarter 2010 Results 2Kendle Announces Third Quarter 2010 Results 3Kendle Announces Third Quarter 2010 Results 4Kendle Announces Third Quarter 2010 Results 5Kendle Announces Third Quarter 2010 Results 6HIPAA 5010 Ready: DST Health Solutions Launches Upgrades of Amisys Advance, PowerMHS, PowerMHC and PowerSTEPP 2HIPAA 5010 Ready: DST Health Solutions Launches Upgrades of Amisys Advance, PowerMHS, PowerMHC and PowerSTEPP 3
(Date:4/17/2015)... 17, 2015 Increasing ... technological advancement to drive biometric systems market in ...   According to a recently released ... &  Opportunities, 2020 ", biometric systems market in ... growth at CAGR of over 22% through 2020. ...
(Date:4/14/2015)... , April 14, 2015 NXT-ID, Inc. ... biometric authentication company focused on the growing mobile commerce ... nominated for the 2015 New York Design Awards under ... Design100, New York City Design Awards are part of ... on over 2,500 ratings from the marketplace, industry and ...
(Date:4/13/2015)... 2015  higi, a leading cloud-based consumer engagement platform ... engage with their communities around health and wellness, announced ... secure API.  ... affordable, and convenient vehicle to receive validated health information ... The API will allow higi,s trusted partners, on ...
Breaking Biology News(10 mins):Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3
... Holdings, Inc. (NYSE MKT: ONVO) ("Organovo"), a three-dimensional biology company ... to present at the 24th Annual Oppenheimer Healthcare Conference, which ... December 10-11, 2013. Organovo,s Chairman and Chief ... Wednesday, December 11, at 2:45pm ET. The objective ...
... soak up a dangerous pore-forming toxin produced by MRSA ... safe and effective vaccine against this toxin. This "nanosponge ... the adverse effects of the alpha-haemolysin toxin from MRSAboth ... the University of California, San Diego described the safety ...
... proteins just beneath its surface until it is trapped as ... hits of energy eventually power the growth and movement of ... life. The three clumps of protein a light-harvesting ... look like random scrawls in illustrations but this is misleading. ...
Cached Biology News:Organovo to Present at the 24th Annual Oppenheimer Healthcare Conference 2'Nanosponge vaccine' fights MRSA toxins 2'Nanosponge vaccine' fights MRSA toxins 3'Nanosponge vaccine' fights MRSA toxins 4Scientists stitch up photosynthetic megacomplex 2Scientists stitch up photosynthetic megacomplex 3
... Nonreversible lids with condensation ... Individual alphanumerical codes for ... for ease in stacking,• ... attachment,• Sterilized by gamma ...
... Cyclin D2 is a G1 cyclin required ... candidate for a proto-oncogene. cyclin D2 ... and/or cdk6. Species Reactivity: Human, Mouse, ... DCS-3.1 MAb is particularly well suited for ...
... The 2/3D Waver Shaker combines shaking and rocking ... a 330 x 330 mm stainless steel or ... incubator and cold room operation. The platform angle ... for a vigorous with action and rotation speed ...
... The PROTEAN II xi 2-D system runs both ... first-dimension IEF tube gels can be separated in a ... onto the cooling core in much the same manner ... are running, the second-dimension slab gels may be cast ...
Biology Products: